AbbVie Inc (ABBV)vsOSR Holdings Inc (OSRH)
ABBV
AbbVie Inc
$227.23
-2.70%
HEALTHCARE · Cap: $380.57B
OSRH
OSR Holdings Inc
$0.42
-1.12%
HEALTHCARE · Cap: $14.13M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2389727% more annual revenue ($62.82B vs $2.63M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. OSRH trades at a lower P/E of 13.4x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
OSRH
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for OSRH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -14.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : OSRH
The strongest argument for OSRH centers on Price/Book, Debt/Equity, P/E Ratio.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : OSRH
The primary concerns for OSRH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
OSRH carries more volatility with a beta of 0.61 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
OSR Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
OSR Holdings Inc. is a prominent provider of integrated managed services, specializing in asset management and financial advisory solutions tailored for institutional clients. Leveraging cutting-edge technology and strategic collaborations, the company enhances operational efficiency while expanding its diverse service portfolio. Committed to sustainable growth and client-centric value creation, OSR Holdings distinguishes itself through innovation and exceptional service quality. With a proactive approach to emerging market opportunities, the firm upholds a robust risk management framework, ensuring long-term stability and success for its stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?